EQL Pharma AB (FRA:7JK) Total Liabilities: €54.20 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7JK EQL Pharma AB FRA:7JK
60 GF Score
Price €2.00
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB Total Liabilities?

EQL Pharma AB FRA:7JK -2.40% 60 Total Liabilities is €54.20 Mil as of Mar. 2026. GuruFocus rates FRA:7JK with a GF Score™ of 60/100. The stock has 4 warning signs investors should review.

EQL Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 was €54.20 Mil.

EQL Pharma AB's quarterly Total Liabilities declined from Sep. 2025 (€51.38 Mil) to Dec. 2025 (€49.97 Mil) but then increased from Dec. 2025 (€49.97 Mil) to Mar. 2026 (€54.20 Mil).

EQL Pharma AB's annual Total Liabilities increased from Mar. 2024 (€17.32 Mil) to Mar. 2025 (€53.66 Mil) and increased from Mar. 2025 (€53.66 Mil) to Mar. 2026 (€54.20 Mil).

EQL Pharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Total Liabilities Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.85 11.67 17.32 53.66 54.20

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.66 51.43 51.38 49.97 54.20
FRA:7JK
60GF Score
EQL Pharma AB FRA:7JK
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

EQL Pharma AB's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.518+(32.046+2.638
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=54.20

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=78.996-24.793
=54.20

EQL Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.518+(32.046+2.638
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=54.20

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=78.996-24.793
=54.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €54.20 Mil mean?
EQL Pharma AB (FRA:7JK) has a Total Liabilities of €54.20 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for EQL Pharma AB and its competitors.
Is EQL Pharma AB's Total Liabilities too high?
EQL Pharma AB's current Total Liabilities is €54.20 Mil. Overall, EQL Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Total Liabilities compare to ZTS and UTHR?
EQL Pharma AB's Total Liabilities of €54.20 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for EQL Pharma AB and its competitors. EQL Pharma AB's current Total Liabilities is €54.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (FRA:7JK) has a current Total Liabilities of €54.20 Mil. The current Total Liabilities is €54.20 Mil. EQL Pharma AB's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For EQL Pharma AB (FRA:7JK), the current Total Liabilities is €54.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges EQL:Sweden7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
60GF Score

Get the complete analysis for FRA:7JK

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price